Trenkwalder Claudia, Högl Birgit, Benes Heike, Kohnen Ralf
Paracelsus-Elena Hospital, Kassel, Germany.
Sleep Med. 2008 Jul;9(5):572-4. doi: 10.1016/j.sleep.2007.07.020. Epub 2007 Oct 24.
Augmentation is a major problem with dopaminergic therapy for restless legs syndrome (RLS), and predictors of augmentation have not yet been identified. We aimed to analyze the relationship between baseline ferritin level and occurrence of augmentation in a retrospective analysis of a prospective double-blind trial of cabergoline versus levodopa on augmentation in RLS.
Patients who experienced augmentation were compared to patients who did not experience augmentation.
Augmentation symptoms causing premature discontinuation from the study or which were tolerated (n=36, ferritin: 85+59 ng/ml) were associated with lower levels of serum ferritin compared to patients without augmentation (n=302, ferritin: 118+108 ng/ml, p=0.0062).
Ferritin as a marker of iron storage may play an important role in the pathophysiology of RLS and may prove to be a biomarker for the development of augmentation under dopaminergic therapy.
症状加剧是不安腿综合征（RLS）多巴胺能治疗的一个主要问题，且尚未确定症状加剧的预测因素。我们旨在通过对一项关于卡麦角林与左旋多巴治疗RLS症状加剧的前瞻性双盲试验的回顾性分析，来分析基线铁蛋白水平与症状加剧发生之间的关系。
将出现症状加剧的患者与未出现症状加剧的患者进行比较。
与未出现症状加剧的患者（n = 302，铁蛋白：118 + 108 ng/ml，p = 0.0062）相比，因症状加剧导致提前退出研究或可耐受的症状加剧患者（n = 36，铁蛋白：85 + 59 ng/ml）血清铁蛋白水平较低。
铁蛋白作为铁储存的标志物，可能在RLS的病理生理学中起重要作用，并且可能被证明是多巴胺能治疗下症状加剧发生的生物标志物。
